1995 - Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes

Presenting Author(s)

• 

  Anthony J. Febres-Aldana, MD (he/him/his)

  Clinical Fellow
  MD Anderson Cancer Center
  Wesley Chapel, FL, United States

  Slides

Co-Author(s)

• FK

  Fareed Khawaja, MBBS

  Assistant Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• AS

  Amy Spallone, M.D.

  University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• KS

  Krithika Srinivasan, MD

  Stanford
  Palo Alto, California, United States
• TS

  Terri Lynn Shigle, PharmD, BCOP

  Clinical Pharmacy Specialist
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• 

  Oscar Morado Aramburo, MD

  Onco-Transplant ID Fellow
  The University of Texas MD Anderson Cancer Center
  houston, Texas, United States
• GR

  Gabriella Rondon, MD

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• JR

  Jeremy Ramdial, MD

  MD Anderson Cancer Center
  Houson, Texas, United States
• ES

  Elizabeth Shpall, MD

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• 

  Ella Ariza Heredia, MD

  Associate Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• 

  Roy F. Chemaly, MD/MPH

  Professor
  MD Anderson
  Houston, Texas, United States
• JS

  Joseph Sassine, MD

  Assistant Professor of Medicine
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma, United States